You Position: Home > Paper
Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders: caution-review of indications and outcome
( views:394, downloads:156 )
- Author:
- No author available
- Journal Title:
- JOURNAL OF LEUKEMIA & LYMPHOMA
- Issue:
- 10
- DOI:
- 10.3760/cma.j.issn.1009-9921.2010.10.001
- Key Word:
- 骨髓增殖性疾病;造血干细胞移植;适应证;微小残留病变;Myeloproliferative disease;Hematopoietic stem cell transplantation;Indication;Minimal residual disease
Abstract： The clinical features were reviewed for polycythemia vera, primary throbocythemia and primary myelofibrosis. Their indications and rational for allogeneic hematopoietic stem sell transplantation (allo-HCT) were recommended. The outcome after allo-HCT was described briefly. The significance of JAK2 mutation, especially V617F, detected for the minimal residual disease was introduced.
- [1]Flowers ME,Linenberger M,Gooley TA,etc.Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.[J].2007,13(3).
- [2]J, Rajantie,G E, Sale,H J, Deeg,etc.Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation.[J].1986,67.
- [3]Holler E,Kobbe,Kroger N.Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.[J].2009,114(26).